VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant testing methods across its oncology research programs, a strategic shift that could improve the predictive value of preclinical data while significantly reducing the number of animals required for drug development. The Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., announced on October 7, 2026, that it is implementing New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays, computational modeling and three-dimensional spheroid models. The move aligns with FDA guidance and reflects a growing industry emphasis on human biology–based testing.
The strategy supports the development of VERAXA’s BiTAC® T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer. According to the company, new three-dimensional spheroid data reinforce the ability of its models to assess the dual-target specificity of its lead T-cell engager candidates. In an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, only about 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. This dramatic reduction in animal use—roughly 95% fewer mice—highlights the efficiency gains of the NAMs approach.
The implications extend beyond animal welfare. By using human-derived cells and advanced modeling, VERAXA aims to generate preclinical data that better predicts how its therapies will perform in patients. This could accelerate the translation of its antibody-based cancer pipeline into clinical trials and reduce the risk of late-stage failures. For investors, the announcement signals a commitment to cost-effective, ethically sound research that may streamline regulatory review. As the FDA and other agencies increasingly embrace NAMs, companies like VERAXA that adopt these methods early may gain a competitive advantage. The company’s progress is detailed in its VERAXA Biotech (NASDAQ: VRXA) profile, and additional updates are available through https://ibn.fm/VRXA. The original release was distributed by www.newmediawire.com.
